Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Juan Angel del Olmo"'
Autor:
Juan José Urquijo, Moisés Diago, M.D., Jaume Boadas, Ramón Planas, Ricard Solá, Juan Angel del Olmo, Javier Crespo, José Carlos Erdozaín, María Dolores Antón, Carlos Arocena, Dolores Suarez, Josep Giné, Josep M Barrera, Javier Gracia-Samaniego, Ricardo Perez, Blai Dalmau, Miguel Montoro
Publikováno v:
Annals of Hepatology, Vol 12, Iss 1, Pp 30-35 (2013)
The hepatitis C virus (HCV) genotype is an important predictive outcome parameter for pegylated interferon plus ribavirin therapy. Most published therapeutic trials to date have enrolled mainly patients with HCV genotypes 1, 2 and 3. Limited studies
Externí odkaz:
https://doaj.org/article/98dcbc9f1b3644c49714f9f6fc02e4a9
Autor:
J M Rodrigo, Juan-Angel Del Olmo, M A Serra, A. Escudero, F Rodríguez, José-Manuel Esteban, Luis Maldonado
Publikováno v:
Ultrasound in Medicine & Biology. 28:297-301
The possibility of assessing the relationship of ultrasound (US)-detected abdominal lymphadenopathy with etiology, biochemical findings, and histologic data in patients with chronic liver disease was evaluated. US examination of the upper abdomen was
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3eaa76743ed3e35724ecbf4278024fdc
https://doi.org/10.1016/s0301-5629(01)00514-2
https://doi.org/10.1016/s0301-5629(01)00514-2
Autor:
Vicente Carreño, José Pedreira, Arturo Pérez-Mota, Juan Antonio Quiroga, Luis Inglada, Dolores Suárez, Angeles Castro, José Such, Esther Carballo, Juan Angel del Olmo, Moisés Diago, Agustín Domínguez
Publikováno v:
Journal of Interferon & Cytokine Research. 17:27-30
The intramuscular administration of interferon-beta (IFN-beta) at a dosage of 6 million units three times per week for 6 months has been evaluated in 90 patients included in a multicenter, randomized, controlled trial for the treatment of chronic hep
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8d5b94d1808243de6eff68641a926b64
https://doi.org/10.1089/jir.1997.17.27
https://doi.org/10.1089/jir.1997.17.27
Autor:
Javier Crespo, Josep Giné, Javier Gracia-Samaniego, Ricardo Perez, Jaume Boadas, Juan José Urquijo, Moisés Diago, M. D. Anton, Josep M Barrera, Dolores Suárez, Carlos Arocena, Ramon Planas, Juan Angel del Olmo, Miguel Montoro, Blai Dalmau, Ricard Solà, J.C. Erdozain
Publikováno v:
Scopus-Elsevier
Annals of Hepatology, Vol 12, Iss 1, Pp 30-35 (2013)
Annals of Hepatology, Vol 12, Iss 1, Pp 30-35 (2013)
The hepatitis C virus (HCV) genotype is an important predictive outcome parameter for pegylated interferon plus ribavirin therapy. Most published therapeutic trials to date have enrolled mainly patients with HCV genotypes 1, 2 and 3. Limited studies
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d74175868533cac9a8b20194eae31442
http://www.scopus.com/inward/record.url?eid=2-s2.0-84878768400&partnerID=MN8TOARS
http://www.scopus.com/inward/record.url?eid=2-s2.0-84878768400&partnerID=MN8TOARS
